Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Discussing the Phase 3 clinical trial of Otsuka and Lundbeck’s Rexulti (brexpiprazole) in patients with agitation from Alzheimer's dementia released at the 2022 Alzheimer's Association International Conference

Ticker(s): OTSKY

Who's the expert?

Institution: Alliance Immediate and Primary Care

Physicians assistant who specializes in family and geriatric medicine
Sees 20-25 patients a month with RSV

Interview Goal

To discuss the standard of care and the potential of Otsuka and Lundbeck’s drug Rexulti (brexpiprazole) for agitation associated with Alzheimer’s dementia (AAD) including the Phase 3 clinical trial of brexpiprazole in patients with Alzheimer's dementia presented at the 2022 Alzheimer's Association International Conference.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.